<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549208</url>
  </required_header>
  <id_info>
    <org_study_id>LG-VECL003</org_study_id>
    <nct_id>NCT03549208</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults</brief_title>
  <official_title>Single-blind, Single-center, Randomized, Active-controlled, Parallel Group, Phase I Study to Evaluate the Safety and Immunogenicity of Intramuscular Single Injection With Pneumococcal Conjugate Vaccine or Prevnar13 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      phase-1 study pneumococcal conjugate vaccine study in healthy adults
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Study to Evaluate the Safety and Immunogeneicity of LBVE(Multivalent Pneumococcal Conjugate
      Vaccine) in Healthy adults
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited adverse events</measure>
    <time_frame>Baseline(pre-vaccination) up to 7 days after</time_frame>
    <description>Solicited adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited adverse events</measure>
    <time_frame>Baseline(pre-vaccination) up to 4 weeks after vaccination</time_frame>
    <description>Unsolicited adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immediate reactions after vaccination</measure>
    <time_frame>Baseline(pre-vaccination) up to 30 minutes after vaccination</time_frame>
    <description>Immediate reactions after vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotype-Specific Pneumococcal immunoglobulin G antibody Geometric Mean Concentrations (GMCs) 4 weeks After Vaccination</measure>
    <time_frame>4 weeks After Vaccination</time_frame>
    <description>GMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 4 weeks After Vaccination</measure>
    <time_frame>4 weeks After Vaccination</time_frame>
    <description>GMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 4-fold rise in Pneumococcal Opsonophagocytic Activity (OPA) titer at 4 weeks after vaccination</measure>
    <time_frame>4 weeks after vaccination</time_frame>
    <description>OPA titer</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pneumococcal Infection</condition>
  <arm_group>
    <arm_group_label>LBVE01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multivalent pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBVE02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multivalent pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multivalent pneumococcal conjugate vaccine Prevnar13</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LBVE01</intervention_name>
    <description>Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh</description>
    <arm_group_label>LBVE01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LBVE02</intervention_name>
    <description>Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh</description>
    <arm_group_label>LBVE02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar13</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh</description>
    <arm_group_label>Prevnar13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult older than 19 years old and younger than 50 years old

          -  A subject who was informed of the purpose, method, and efficacy of the clinical study
             and signed the written informed consent form

        Exclusion Criteria:

          -  A subject who participated in other clinical studies within 3 months before screening

          -  A subject who was vaccinated with other vaccines within 4 weeks before screening, or
             who is expected to receive other vaccination during the clinical study period

          -  A subject with medical history of hypersensitive reactions (e.g. anaphylaxis) to the
             test drug or its ingredients

          -  A subject who received immunoglobulin or blood-derived materials within 3 months
             before screening

          -  A subject with immunologic function disorders including congenital or acquired
             immunodeficiency disorders

          -  A subject who is receiving immunosuppressive therapy or drugs that can affect
             immunological reaction

          -  A subject with pyrexia of over 38 Celsius degrees on the day of the vaccination with
             the investigational products

          -  A subject with medical history of Invasive Pneumococcal Disease (IPD) or pneumonia
             caused by Streptococcus pneumoniae

          -  A subject who was vaccinated with any pneumococcal vaccine before screening

          -  A subject who received the vaccine containing diphtheria toxoid within 6 months before
             screening (e.g. adult Td vaccine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myoung-don Oh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soie Park</last_name>
    <phone>02-6987-4160</phone>
    <email>soiep@lgchem.com</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

